NCT00313781 - Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2011

Study Completion Date

December 31, 2011

Conditions

Prostatic Neoplasms

Interventions

DRUG

CP-751,871

CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).

DRUG

docetaxel

Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.

DRUG

prednisone

Prednisone is administered at a dose of 5 mg twice daily.

DRUG

docetaxel

Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.

DRUG

prednisone

Prednisone is administered at a dose of 5 mg twice daily.

Trial Locations (18)

10032

Pfizer Investigational Site, New York

12200

Pfizer Investigational Site, Berlin

15006

Pfizer Investigational Site, A Coruña

44106

Pfizer Investigational Site, Cleveland

44122

Pfizer Investigational Site, Orange

81675

Pfizer Investigational Site, München

90048

Pfizer Investigational Site, Los Angeles

44195-0001

Pfizer Investigational Site, Cleveland

19111-2497

Pfizer Investigational Site, Philadelphia

H2L 4M1

Pfizer Investigational Site, Montreal

H3T 1E2

Pfizer Investigational Site, Montreal

08035

Pfizer Investigational Site, Barcelona

08907

Pfizer Investigational Site, L'Hospitalet de Llobregat

CH-9007

Pfizer Investigational Site, Sankt Gallen

SM2 5PT

Pfizer Investigational Site, Sutton

G12 0YH

Pfizer Investigational Site, Glasgow

G52 3NQ

Pfizer Investigational Site, Glasgow

GU2 7WG

Pfizer Investigational Site, Guildford